A high-yield isolation and enrichment strategy for human lung microvascular endothelial cells

Christa Gaskill1 and Susan M. Majka1,2
1Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN, USA; 2Vanderbilt Center for Stem Cell Biology, Vanderbilt University, Nashville, TN, USA

Abstract
Vasculopathies, characterized by the formation of fragile and abnormal microvessels, are associated with the severity of many chronic lung diseases, including pulmonary fibrosis, emphysema/chronic obstructive pulmonary disease, systemic sclerosis, and hypertension. However, the study of human lung vasculature has been limited by the ability to isolate generous quantities of microvascular endothelial cells (MVEC) free from mesenchymal contamination. Expansion and passaging of primary human MVEC in vitro typically results in loss of a traditional phenotype in favor of an intermediate mesenchymal one, as early as passage five. Here we provide a detailed protocol for the selection of large quantities of enriched primary human lung MVEC based upon differential adherence from mesenchyme and simple magnetic separation, which decreases the need for excessive passaging, in order to obtain sufficient cell numbers to successfully freeze stock cultures. Additional protocols are provided for Ac-di-LDL selection, characterization, and a sandwich angiogenesis method of functional tube formation. The complete protocol including cell isolation and characterization takes approximately six weeks to complete.

Keywords
lung microvascular endothelial cells, primary cells

Date received: 27 September 2016; accepted: 5 October 2016
Pulmonary Circulation 2017; 7(1) 108–116
DOI: 10.1177/2045893217702346

Introduction
The pulmonary microvasculature is the primary site for gas exchange in the lung, facilitating oxygenation of red blood cells and excretion of carbon dioxide. Pathological changes in the pulmonary microvasculature may both precede and/or exacerbate a number of chronic adult lung diseases, including but not limited to pulmonary fibrosis (PF), chronic obstructive pulmonary disease (COPD), and connective tissue diseases including systemic sclerosis (SSc). Additionally, vascular remodeling may result in pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH) associated with PF, COPD and SSc. Pulmonary vasculopathies, also known as vascular dysfunction or disease (PVD), are characterized by dysfunctional vascular structure and function. PVD is believed to be asymptomatic until severe, when approximately 50–70% of the pulmonary vascular bed is lost and pulmonary vascular resistance and pulmonary artery pressure rises leading to the clinical presentation and diagnosis of PH.1 Considerable progress has been made in understanding the role that various cell populations, including endothelial cells, smooth muscle cells, and fibroblasts, play in the remodeling that defines vascular dysfunction during disease. However, our current understanding of the cell-based mechanisms are incomplete, demonstrating a need for primary vascular cell types to further study and understand disease processes. To overcome this limitation, we sought to develop a robust method based on the inherently different properties of cell adhesion, between MVEC and lung mesenchymal cells, in order to enrich for primary lung MVEC. Because expansion of

Corresponding author:
Susan M. Majka, Vanderbilt University, Division of Allergy, Pulmonary and Critical Care Medicine, 1161 21st Ave S T-1218 MCN, Nashville, TN 37232, USA.
Email: susan.m.majka@vanderbilt.edu

Creative Commons Non Commercial CC-BY-NC. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
primary human MVEC in vitro typically results in loss of phenotype in favor of an intermediate mesenchymal one, we hypothesized that if a substantial number of viable MVEC could be enriched from explanted lung tissue quickly following isolation, a greater number of stock lines could be created. Here we provide a detailed protocol for the selection of enriched primary human lung MVEC, based upon differential adherence and simple magnetic separation, decreasing excessive passaging. Enrichment and lineage specificity was documented by Ac-di-LDL uptake, characterization by flow cytometry, quantitative polymerase chain reaction (qPCR) and immunofluorescent staining as well as a sandwich angiogenesis assay of functional tube formation.

**Methods**

**Isolation of adherent cell fractions from lung tissue explants**

Human explanted lung tissue was isolated post transplant or autopsy in 1-in. cubes stored in DMEM (Vanderbilt IRB Protocol 9401). The viability and quantity of cells obtained from post-transplant tissue is significantly greater than post-autopsy tissue.

Tissue was minced to achieve the consistency of paste in a 100-mm dish, using scissors and disposable scalpels. minced tissue was then transferred to a solution of Type II collagenase (Worthington sterile filtered; LS004202) in Hank’s balanced saline (HBSS; resuspend lyophilized container in approximately 35 mL to yield 515 U/mL). For fibroblast (FB) isolation, tissue was transferred to 23 mL of collagenase in a 50-mL conical tube (per cube). For the MVEC isolation, tissue is transferred into a total of 90 mL of collagenase with attachment factor (AF) (Life Technologies S-006-100; 16–20 h later the media was changed to remove collagenase (Worthington sterile filtered; LS004202); 16–20 h later the media was changed to remove debris. At 24 h, post-plating, additional heparin (0.75 U/mL) was added to the complete LONZA medium, in order to decrease FB/mesenchymal growth. Within 48–72 h, the cells spread and assumed characteristic phenotypes. Heparin was added only after the cells had adhered because it can decrease attachment.

To passage the MVEC cell prep, flasks were washed with DPBS followed by the application of Versene (Gibco 15040-066). Flasks were placed in the incubator for 1 min at a time and subsequently viewed to identify that 100% of the cells had lifted. The lifted cells were plated onto AF coated flasks (passage 1). When flasks were nearly confluent (day 12 post isolation), cells were lifted with Versene and magnetic bead separation was performed using CD31/PECAM, according to the manufacturer’s instructions (Miltenyi kit no 130-091-935; passage 2), with the following exception: use PBS + 2% FBS as buffer and omit the kit blocking instructions. Two million cells were separated on the column. Upon subsequent passages, we performed a quick first pass lift with Versene, in order to deplete FB, further enriching for MVEC (which remain adherent). The flasks were viewed closely and gently tapped to remove FB. Tryptsin was applied to quickly lift and pass the remaining enriched MVEC. Further enrichment may be performed by incubating 50–75% confluent MVEC in Ac-di-LDL-Alexa 488 (Life Technologies L23380) at 10 g/mL in growth media. Flow cytometry may be used to sort out the cells with the highest peak fluorescence. FB passing was performed using trypsin and standard protocols. MVEC were always cultured on AF coated flasks.

**Acetyl-di-LDL uptake**

MVEC cells approximately 75% confluent (3,000,000 at this stage; passage 4, day 31) were incubated with 5–10 ug/mL acetylated (Ac-di LDL-Alexa 488 (Life Technologies L23380) in growth medium for 3 h. Known positive and negative controls were also prepared to set sorting gates. In this case, pulmonary artery endothelial cells (PAEC; LONZA CC-2530) were used as a positive and lung FB as a negative control.

Ac-di-LDL was then removed and cell rinsed once with HBSS and trypsinized for approximately 2 min using standard protocols. Four volumes of complete media were immediately added to inhibit the trypsin. FACS was employed to sort and collect on the top 50% or more positive fluorescent fraction based on the fluorescence intensity of positive and negative control cells. FB were used as a negative control for Ac-di-LDL uptake to set the selection gates. Using the BD FACS Aria III (BD Biosciences, San Jose, CA, USA) the recommended wavelengths used for cell sorting included: excitation = 488 nm, emission = 550 nm. Sorted cells were collected into complete growth medium and re-plated in AF coated T25 flasks. Additional heparin is unnecessary for maintenance of these cultures at this stage.

**MVEC characterization**

Flow cytometry was used to characterize cell surface determinant expression by MVEC using standard protocols.3–6 The cells were stained with antibodies to detect the markers presented in Table 1 using a BD FACS Aria III (BD Biosciences, San Jose, CA, USA). Fluorescent minus one (FMO) and isotype (eBioscience, San Diego, CA, USA) controls were used to set the gates. DAPI was used to exclude dead cells.
The compensation controls were established as cells only, cells + DAPI, cells + APC antibody, cells + PE antibody, cells + FITC antibody, alternatively comp beads were used. The gating strategy routinely included forward scatter/side scatter (FSC)/SSc, single cells gated by SSC-Width/SSC-Height (SSC-W/SSC-H), FSC-W/FSC-H, DAPI to gate out dead cells. A summary of antibodies is presented in Table 1. Known positive and negative controls were also prepared to set sorting gates. In this case, PAEC (LONZA CC-2530) were used as a positive control and lung FB as a negative control. qPCR and immunofluorescent staining were performed to demonstrate the relative expression of endothelial marker transcript and protein using standard methods. A summary of PCR primers is presented in Table 1.

**Table 1. Reagents.**

| Antibodies | Vendor | Ref no. |
|------------|--------|---------|
| CD144      | PE     | ebio    | 12-1449-80 |
| CD105      | PE     | ebio    | 12-1057-41 |
| CD106      | PE     | Ebio    | 12-1069-41 |
| CD338      | PE     | BD      | 561180     |
| B220       | PE     | ebio    | 12-0452-82 |
| CD31       | PE     | BD      | 555446     |
| CD146      | FITC   | ebio    | 11-1469-41 |
| CD34       | FITC   | ebio    | 11-0349-42 |
| CD14       | FITC   | ebio    | 11-0149-42 |
| CD44       | FITC   | ebio    | 11-0441-82 |
| CD45       | APC    | ebio    | 17-9459-42 |
| CD73       | APC    | ebio    | 17-0739-41 |
| Isotype    | APC    | BD      | 555745     |
| CD102      | FITC   | ebio    | 328507     |

**Human PCR primers**

| Primer    | Fw          | Rv          |
|-----------|-------------|-------------|
| CDH5 (VE Cadherin) | TTGGAAACCAGATGCACATTGAT | TCTTGCGACTCAGCTTTGAC |
| PECAM     | CCAAGGTTGGATCGTGGAGG | TCAGGAGTAAAGCCGGGTC |
| VWF       | CGGATGCAGCCTTTTCCGA | TCCCCAAGATACCCGAGGAG |
| Tie2      | TTAGCCAGCTTGATTCGCTTGTGG | AGCATACTACAAAGAGTGGG |
| ACTA2     | CTTTTGCGCTTGCTTGTCAG | GGGGGGACACGAGGAGGAG |
| FLK (VEGFR2) | GGCCTGCACATTGAGGCTGGCA | CCAGTGTCATTCCGATCATT |
| FLT1      | TTGGCCCTGGAAATGGTGAGTGG | TTGGCCCTGGAAATGGTGAGTGG |
| PDGFRB    | GATGCTAGTGCTCCAGTCTTC | GAGGTTGCTCTACCTTGG |
| CSPG4     | Applied Biosystems | Hs00361541_g1 |

**Tube-forming assay: sandwich method**

Tissue culture treated two-chamber slides (Lab-Tek 154852) were pre-chilled overnight and coated with 400 microliters diluted Matrigel (Corning 354264, San Jose, CA, USA). For these studies, high concentration Matrigel was diluted 1:1 with ice-cold growth media before use. Matrigel was allowed to polymerize at 37°C for 45 min. Concurrently, cells from all lines were trypsinized, filtered, and centrifuged to be resuspended at $1 \times 10^5$ cells/mL in growth media. A preparation was made by further diluting our Matrigel working stock to 4% in ice-cold growth media. Cells were mixed in equal volume with the low concentration Matrigel mixture to achieve a final concentration of $5 \times 10^4$ cells/mL in 2% Matrigel. A total of 750 microliters was applied to
each chamber. Slides were incubated at 37°C 5% CO2 and
and tube formation was photographed starting at 30 min after
plating to 4 h when a significant degree of tube formation
had occurred. In all experiments, FB were cultured using
20% FBS αMEM (Life Technologies 12571-063) while
endothelial cells (PAEC and MVEC) were cultured in
EBM-2 with EGM-2 MV SingleQuots (Lonza CC-3156,
CC-4147).

Results
Pulmonary MVEC or FB isolation and morphology
Primary cell isolation and characterization were performed
to obtain primary MVEC and FB from lung tissue explants
(Fig. 1a and c). Lung mesenchymal stem cells (MSC) were
also isolated from FB as previously described2,3 (Fig. 1b).
The identification of optimal conditions to obtain single cell
suspensions from fresh distal lung tissue allowed the initial
selection between the two cell types. A higher yield of
MVEC was obtained with the increased ratio of collagenase
to tissue relative to that of lung FB. Second, plating cells on
a gelatin substrate, at a density to allow for colony forma-
tion following adherence, aided in the identification and fur-
ther enrichment of MVEC. Purification was performed
exploiting their expression of PECAM1/CD31. Primary
CD31 antibody conjugated to a magnetic bead was used
in combination with a magnetic column. CD31 expressing
MVEC was positively selected (Fig. 1e–g). MVEC colonies
comprising 50 or more cells appeared more resistant to
detachment during Versene treatment, while the mesenchy-
mal cells readily detached (Fig. 1d). Removal of the mesen-
chymal cells at this stage allowed for expansion of a highly
enriched population of MVEC. The addition of heparin also
attenuated residual mesenchymal proliferation, likely
through modulation of growth factor signaling.8

Analysis and enrichment of human lung MVEC
by Ac-di-LDL uptake
To analyze the relative purity of MVEC and perform a fur-
ther enrichment step, Ac-di-LDL uptake was used. Di LDL
has been utilized for over 20 years to purify EC in culture
from contaminating tissue mesenchymal cells.9 Lung cells
were incubated with fluorescent labeled Ac-di-LDL, ana-
alyzed, and sorted by flow cytometry (Fig. 2). Primary lung
FB were used as a negative control to set the gates, distin-
guishing between positive and negative populations. The
lung FB demonstrated less than 0.5% positive uptake of
the Ac-di-LDL. There was a clear separation between the
negative and positive populations of MVEC, which were
93.0% positive for Ac-di-LDL uptake. Starting with
3,000,000 cells, approximately 1,850,000 cells were identified
as positive and appropriate for sorting. Enrichment of the
MVEC population at this stage may only be necessary for
specific analyses. The purity of the sorted population was
100% (Fig. 2). Ac-di-LDL uptake distinguishes the MVEC
from lung mesenchymal FB.
Lung MVEC expression of endothelial lineage cell surface markers distinct from the tissue mesenchyme

Lung cells were incubated with primary antibodies directly conjugated to fluorophores and staining intensity analyzed by flow cytometry to quantitate their expression of the endothelial lineage markers, CD144/VE-cadherin, CD31/PECAM1, CD102/ICAM2, CD105/Endoglin, CD73, CD146/MCAM, CD34, and CD44 (Fig. 3). PAEC were used as a positive control, FB and lung MSC as negative controls. All cell lines were negative for the expression of hematopoietic markers CD45, B220, and CD14. The EC universally expressed CD144, CD31, CD102, CD105, CD73, CD146 and were negative for CD338 (ABCG2). The MVEC heterogeneously expressed CD34 (24%), CD106 (0.58%), and CD44 (93%). Lung FB heterogeneously expressed CD106 (1.65%) and CD338 (3.2%) and were negative for the EC markers CD144, CD31, and CD102. The MVEC and PAEC overlapped in their cell surface expression of all the markers with the exception of CD44 (PAEC 73%; MVEC 93%). The MVEC were clearly distinct from the FB and MSC, overlapping only in their expression of CD105, CD73, and CD44. Interestingly CD146, 73, 44, and 105 are also considered MSC markers and are routinely used in the panel to define MSC.13

Transcriptional and intracellular expression of endothelial markers by primary lung MVEC

To further define the endothelial characteristics of the primary lung MVEC and distinguish them as distinct from the tissue resident mesenchymal fractions, we performed qPCR analyses using human lung MVEC, PAEC, FB, and MSC. Relative levels of gene expression were quantitated for endothelial lineage markers VECAD, PECAM1, VWF, TIE2(TEK), the vascular endothelial growth factor receptors, FLT1 and FLK, and the pericyte/mesenchymal lineage marker, PDGFRβ (Fig. 4a).10–12 MVEC expressed relatively high levels of all the EC markers and were negative for PDGFRβ. Lung MSC expressed high levels of PDGFRβ and low levels of Flt1. Immunostaining was also performed to detect and localize Factor VIII or VE-cadherin in isolated primary lung MVEC. As expected, Factor VIII localized to inclusion bodies in the cytoplasm of the cells while VE-cadherin localized to the tight junctions between the MVEC as well as the cytoplasm (Fig. 4b).

MVEC demonstrate tube-forming ability in vitro

A Matrigel sandwich method was used to analyze functional tube-forming ability of the primary lung MVEC. PAEC were
Fig. 3 Expression of endothelial cell surface determinants by primary lung MVEC. Lung cells were incubated with primary antibodies directly conjugated to fluorophores and staining intensity analyzed by flow cytometry. Representative dot plots are presented. Human lung FB and MSC were used as known negative controls, and PAEC as a known positive control. DAPI was used to exclude dead cells.
used as a positive control and primary lung FB as a negative control. At 4 h, both PAEC and primary lung MVEC formed characteristic angiogenic tube structures (Fig. 5). In contrast, lung FB formed clusters or cord-like structures.

**Discussion**

Obtaining reasonable yield of primary human lung MVEC from tissue explants free from mesenchymal contamination at low passage, and with traditional morphology and endothelial characteristics, has posed a significant challenge. This limitation coupled to the availability of tissue has resulted in studies of the pulmonary microvasculature being conducted with small numbers of patient primary cell lines (n number), variable experimental outcomes due to variation in cell phenotypes and purity, as well as the use of animal cells for a majority of studies. To address our hypothesis, we evaluated the use of positive selection of MVEC based on differential adherence characteristics distinct from tissue mesenchymal cells, specifically FB. Using a protocol for the selection of enriched primary human lung MVEC, based upon differential adherence and simple magnetic separation, we demonstrated enrichment and lineage specificity by Ac-di-LDL uptake, characterization by flow cytometry, qPCR, and immunofluorescent staining as well as functional angiogenic tube formation. This protocol is scalable and may be used to obtain a large number of enriched control and disease patient lung MVEC. These reported techniques expand upon recently published protocols for the isolation of pulmonary MVEC.14–16 The use of magnetic bead separation of MVEC is similar to the protocol previously published by Mackay et al.16 in which positive bead selection was used to achieve 1–9 million MVEC by passages 4–6 from 50 g of lung tissue, with the reported purity in the range of approximately 77–90%. Here we achieved 3 million cells, at low passage, from a small section of explanted lung, approximately 3 g.

Significant variations in the protocols that may have increased our yield included the adherence step we utilized following tissue digest, as well as the use of supplemental heparin to decrease mesenchymal proliferation. The adherence step facilitated the removal of tissue debris and dead cells versus the use of a 100 micrometer filter, which likely removes the clusters of MVEC that should appear as
"beads on a string" following digest due to their tight cell–cell contacts and basement membrane. The MVEC cultures were also plated to achieve less than 30% confluence, in order to allow colonies to expand in size. The second published protocol utilized the clustering of MVEC following digest to select them using a filtration step. Comhair et al.\textsuperscript{14} digested lung tissue explants for a brief interval of 20 min, then, using applied pressure, forced clusters of MVEC from the tissue. Isolated cells were filtered and EC clusters rinsed from the top of the filter and plated on fibronectin-coated plastic. The investigators also used supplemental heparin to control contaminating mesenchymal growth. However, it was unclear how the contaminants were removed, what yield or purity was achieved, as only isotype antibodies were used as controls for flow cytometric characterization. Generalized isolation of MVEC from tissue was also reported by van Beijnum et al.\textsuperscript{17} using either magnetic separation or flow cytometry enriching by CD31, CD34, CD146, or CD105.

Our data demonstrate that CD34 expression is highly variable and CD146 and CD105 are not specific to MVEC. As expected CD31, VE-cadherin and ICAM2 were expressed by EC, and not lung mesenchymal cells, FB, or MSC. Following digest of 1 g of tissue the investigators could identify and sort approximately 1,000,000 cells with 90% purity; however, their yield of viable cells was not reported.

The most significant findings from this study comparing the primary human MVEC with lung FB and MSC was that the MVEC colonies maintained their adherence and contacts during brief Versene treatment, which allowed for their further selection and expansion, without passaging and separating them. The culture of MVEC colonies, versus independent cells after passaging, may facilitate the maintenance of their morphology, characterized by tight junctions and basement membrane. The maintenance of the MVEC cell–cell contacts during isolation is also the underlying reason that isolating primary EC from tissue digests by flow cytometry, which inherently requires single cell suspensions, typically results in a low yield of viable cells. An additional concern with flow cytometric isolation of MVEC is the damage to the cell membranes necessary to obtain a single cell suspension. In contrast, circulating EC or EC progenitors that may be successfully isolated using flow cytometry.\textsuperscript{18}

Taken together our results demonstrate that this protocol, based on selective adhesion, efficiently enriches for human lung MVEC. Thus, building upon existing protocols and providing a straightforward method for rapid and higher yield isolation of MVEC from explanted lung
tissue. This higher yield of lower passage cells should serve as a resource for many investigators interested in preparing MVEC stock for the study of pulmonary microvasculature.

Acknowledgments
The authors thank Jonathan Kropski, M.D. and Joshua Fessel M.D., Ph.D, for their provision of tissue explants as well as the expert technical assistance provided by Catherine E. Alford and the Research Flow Cytometry Laboratory at the Nashville VA Medical Center and Karen Helm in the University of Colorado Cancer Center’s Flow Cytometry Shared Resource (P30-CA046934 NCI).

Conflict of interest
The author(s) declare that there is no conflict of interest.

Funding
This work was funded by grants to S.M. Majka from the NIH R01HL091105 and NIH R01HL11659701. Additional funding was also provided by PPG-5P01HL108800-04 (PI: J. Loyd) and PPG-2 P01 HL 092870-06 (PI: T. Blackwell). The project was supported in part by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06.

References
1. Austin ED, Kawut SM, Gladwin MT, et al. Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. *Ann Am Thorac Soc* 2014; 11(Suppl. 3): S178–S185.
2. Gaskill C, Marriott S, Pratap S, et al. Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in PAH: Identifying key pathways in pulmonary vascular disease. *Pulm Circ* 2016; 6(4): 483–497.
3. Marriott S, Baskir RS, Gaskill C, et al. ABCG2(pos) lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. *Am J Physiol Cell Physiol* 2014; 307(8): C684–C698.
4. Martin J, Helm K, Ruegg P, et al. Adult lung side population cells have mesenchymal stem cell potential. *CytOTHERAPY* 2008; 10(2): 140–151.
5. Chow K, Fessel JP, Kaori Iida S, et al. Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling. *Pulm Circ* 2013; 3(1): 31–49.
6. Alvarez DF, Helm K, DeGregori J, et al. Publishing flow cytometry data. *Am J Physiol Lung Cell Mol Physiol* 2010; 298(2): L127.
7. West JD, Austin ED, Gaskill C, et al. Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. *Am J Physiol Cell Physiol* 2014; 307(5): C415–C430.
8. Kendall RT and Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. *Front Pharmacol* 2014; 5: 123.
9. Voyta JC, Via DP, Butterfield CE, et al. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. *J Cell Biol* 1984; 99(6): 2034–2040.
10. Armulik A, Abramsson A and Betsholtz C. Endothelial/pericyte interactions. *Circ Res* 2005; 97(6): 512–523.
11. Birbrair A, Zhang T, Files D, et al. Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. *Stem Cell Res Ther* 2014; 5(6): 122.
12. Paquet-Fifield S, Schluter H, Li A, et al. A role for pericytes as microenvironmental regulators of human skin tissue regeneration. *J Clin Invest* 2009; 119(9): 2795–2806.
13. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8(4): 315–317.
14. Comhail SAA, Xu W, Mavrakis L, et al. Human primary lung endothelial cells in culture. *Am J Respir Cell Mol Biol* 2012; 46(6): 723–730.
15. Bryant AJ, Carrick RP, McConaha ME, et al. Endothelial HIF signaling regulates pulmonary fibrosis associated pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 2016; 310(3): L249–262.
16. Mackay LS, Dodd S, Dougal IG, et al. Isolation and characterisation of human pulmonary microvascular endothelial cells from patients with severe emphysema. *Respir Res* 2013; 14(1): 1–11.
17. van Beijnum JR, Rousch M, Castermans K, et al. Isolation of endothelial cells from fresh tissues. *Nat Protocols* 2008; 3(6): 1085–1091.
18. Khan SS, Solomon MA and McCoy JP. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. *Cytometry B Clin Cytom* 2005; 64B(1): 1–8.